Skip to content

Non-invasive Home Ventilation in Patients With Severe Hypercapnic Chronic Obstructive Pulmonary Disease

Non-invasive Home Ventilation in Patients With Severe Hypercapnic COPD: Standard Versus Löwenstein Mode of Management of Dynamic Hyperinflation; Effects on Hematosis and Sleep.

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03934749
Acronym
SOMNOVENT'
Enrollment
1
Registered
2019-05-02
Start date
2019-06-27
Completion date
2020-09-27
Last updated
2021-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease, Hypercapnia

Brief summary

In COPD patients with chronic hypercapnic respiratory failure, the prognosis is poor and the treatment with non invasive ventilation is actually well established. However the best mode of ventilation is not well known. In severe COPD patients various disorders of respiratory mechanics result in insufficient ventilation, which can be life-threatening or create NIV discomfort. The main characteristic of these disorders is a cyclical closing of small airways that can limit an expiratory flow and provoked some fluctuations in flow curve. To our knowledge, the management of dynamic hyperinflation seems to play an important role in explaining the effect of the NIV. Few studies have examined the effects of the machine's adjustments on dynamic hyperinflation. The main objective of this study is to analyze the impact of specific ventilatory modes supposed to reduce the dynamic hyperinflation on the hematosis, by studying transcutaneous pressure of carbon dioxide, in severe hypercapnic COPD patients ventilated by NIV. Two modes of ventilation will be compared. First one is an algorithmic mode developed by the company Löwenstein (AirTrap Control, Trigger Lockout and the Expiratory Pressure Ramp). The second one is a standard algorithmic mode, used in the same ventilator. These two ventilatory modes will be evaluated in each patient, during two consecutive nights in current living conditions at home.

Interventions

DEVICENon Invasive Ventilation

NIV using standard mode or Lowenstein mode

Sponsors

Centre Hospitalier Universitaire de Besancon
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Diagnosis of COPD using Gold 2017 criterion * Optimal medical treatment of COPD, ie. inhaled steroids, long-acting β2-agonist, long-acting anticholinergic, according to GOLD 2017 guidelines. * At least one acute exacerbation of COPD with hypercapnic respiratory failure * Introduction of NIV distant to acute exacerbation of COPD with persisting hypercapnia (\> 7kPa) on arterial blood gas at rest. * NIV equipment from the service provider Don Du Souffle (DDS). * Patient able to give their consent

Exclusion criteria

* Contraindication to NIV (consensus conference of SFAR-SPLF-SRLF) * Obstructive sleep apnea with apnea/hypopnea index \> to 20/h * BMI \> 35 kg/m2 * Low compliance with NIV treatment (\<3h per day) * Acute exacerbation COPD during inclusion or pH \<7.30 in routine blood gas arterial * Severe heart failure (New York Heart Association stage IV/IV) * Unstable angina * Severe arrhythmias * Severe renal insufficiency stage \> 4 * Other conditions than COPD resulting in hypercapnia * Pregnancy * Patient without health insurance * Patient excluded by another study

Design outcomes

Primary

MeasureTime frameDescription
Mean carbon dioxide partial pressure-level during non invasive ventilation2 nightsMean pCO2 level over night calculated using transcutaneous measurement of partial pressure of carbon dioxide under non invasive ventilation. Device : transcutaneous capnography (PtcCO2); SenTec Digital Monitoring System

Secondary

MeasureTime frameDescription
Number of respiratory events during non invasive ventilation2 nightsAccording to consensus group, nocturnal respiratory events are : unintentional leak, obstruction at different levels of the upper airways and asynchrony (ineffective effort, auto-triggering, and double triggering, premature or delayed cycling)
Sleep quality2 nightsChanges in data of polysomnography (total sleep time (TST) ; total recording time ; sleep latency, sleep efficiency (TST/time in bed) ; time in each stages plus percent of TST in each stage ; stage REM latency ; wake time after sleep onset ; arousal index)
Ventilation quality2 nightsSubjective changes in quality of ventilator by specific auto questionnaire (quality of night, feeling, dyspnea, quality of ventilation, respiratory disturbance caused by NIV, sleep disturbance caused by NIV). The patient answers to each question using a likert scale in terms of intensity. The second questionnaire is the S3-NIV which is a tool for the routine clinical assessment of patients undergoing home NIV.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026